Field practice study of half‐dose sorafenib treatment on safety and efficacy for hepatocellular carcinoma: A propensity score analysis
Manabu Morimoto(Kanagawa Prefectural Hospital Organization), Katsuaki Tanaka(Yokohama City University Medical Center), Kazushi Numata(Yokohama City University Medical Center), Satoshi Kobayashi(Kanagawa Cancer Center), Takahide Nakazawa(Kitasato University Hospital), Masaaki Kondo(Yokohama City University Medical Center), Kotaro Matsunaga(St. Marianna University School of Medicine), Satoshi Morita(Kyoto University), Chiaki Okuse(St. Marianna University School of Medicine), Yusuke Okuwaki(Kitasato University), Shinichi Ohkawa(National Cancer Center Hospital East), Hisashi Hidaka(Kitasato University), Michihiro Suzuki(Tamagawa University), Masataka Taguri(Yokohama City University)
Cited by 30
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells.
|Journal of Biological Chemistry|1990|1.5k